Top Rated Rabeprazole Brands for Reliable Relief

Rabeprazole is a popular proton pump inhibitor used to treat conditions such as GERD and Zollinger-Ellison syndrome by reducing stomach acid production. With its increasing demand, numerous pharmaceutical companies have stepped up to offer high-quality formulations of rabeprazole. From generic brands to those with a more established pedigree, the market is teeming with options for consumers and healthcare professionals alike. Below, we highlight some of the best brands that have consistently been recognized for their quality and efficacy in providing rabeprazole formulations.

Illustration of rabeprazole

Best brands of rabeprazole in 2025

ACIPHEX®

ACIPHEX^(r) (rabeprazole sodium) by Eisai is a prominent proton pump inhibitor (PPI) widely used for treating gastroesophageal reflux disease (GERD) and other acid-related gastrointestinal diseases. Launched in Japan in 1997, Europe in 1998, and the United States in 1999, ACIPHEX has gained a significant market share, with around 10% of the PPI market despite strong competition. The drug has been approved in over 90 countries and is known for its efficacy in healing and maintaining the healing of erosive or ulcerative GERD, as well as treating Helicobacter pylori infections. ACIPHEX was also granted additional six months of U.S. market exclusivity in 2012 due to pediatric exclusivity requirements. It has been a key product for Eisai, contributing significantly to the company's growth. For more details, visit their official drug information page.

Pariet®

Pariet(r) by Janssen Pharmaceuticals is a leading brand for rabeprazole sodium, a proton pump inhibitor (PPI) used to treat conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison Syndrome. It is known for its rapid onset of action, with studies showing that rabeprazole provides faster relief from heartburn symptoms compared to other PPIs like omeprazole and lansoprazole. The global rabeprazole sodium market, which includes Pariet(r), is projected to grow at a CAGR of 4% from 2024 to 2031, reaching a market size of USD 896.41 million by 2031. In 2024, the North American market, where Pariet(r) is prominent, held over 40% of the global revenue with a market size of USD 272.48 million. Pariet(r) tablets are available in 10 mg and 20 mg doses and are designed to lower stomach acid production effectively.

Rabeprazole Sodium

Dr. Reddy's Laboratories is a leading manufacturer of Rabeprazole Sodium, known for its high-quality and reliable active pharmaceutical ingredients (APIs). The global Rabeprazole Sodium market, driven by the increasing prevalence of GERD and peptic ulcers, is expected to grow from USD 681.2 million in 2024 to USD 896.41 million by 2031, with a CAGR of 4.00%. Dr. Reddy's API business thrives on deep technical strengths and stringent quality control measures, making it a preferred partner for pharma companies globally. The company's expertise in R&D, IP, and regulatory affairs ensures compliance with the latest standards of quality, safety, and productivity. With a strong supply chain, Dr. Reddy's can quickly respond to market demands and avoid shortages.

Rabeprazole Sodium

Rabeprazole Sodium, particularly from Teva Pharmaceuticals, is a leading brand in the market, known for its efficacy in treating gastroesophageal reflux disease (GERD) and peptic ulcers. The global Rabeprazole Sodium market, which includes Teva Pharmaceuticals as a key player, was valued at $681.2 million in 2024 and is projected to grow at a CAGR of 4.0% from 2024 to 2031, reaching $896.41 million by 2031. North America, where Teva Pharmaceuticals has a significant presence, held more than 40% of the global revenue in 2024. The market growth is driven by the high prevalence of gastrointestinal disorders and the advanced healthcare infrastructure in the region. Teva Pharmaceuticals, along with other major players, contributes to the market's consolidated competitive landscape.

Rabeprazole Sodium

Rabeprazole Sodium (Sandoz) is a prominent brand in the proton pump inhibitor (PPI) market, known for its effectiveness in reducing stomach acid production. It is used to treat conditions such as duodenal ulcers, Zollinger-Ellison syndrome, and gastroesophageal reflux disease (GERD), and can be combined with antibiotics like amoxicillin and clarithromycin to treat H. pylori infections. The global rabeprazole sodium market, which includes Sandoz Rabeprazole, is projected to grow at a CAGR of 3.8% from 2022 to 2031, reaching $895.85 million by 2031. Sandoz Rabeprazole is available in 10mg and 20mg enteric-coated tablets, ensuring controlled release and optimal efficacy. For more detailed information, explore their official product details.

Rabeprazole Sodium

Rabeprazole Sodium, manufactured by Aurobindo Pharma, is a leading proton pump inhibitor (PPI) indicated for various gastrointestinal conditions, including GERD and duodenal ulcers. The global Rabeprazole Sodium market, driven by the increasing prevalence of GERD and peptic ulcers, is expected to grow from USD 681.2 million in 2024 to USD 896.41 million by 2031, with a CAGR of 4.00%. Aurobindo Pharma's formulation is available in 20 mg delayed-release tablets and is contraindicated in patients with known hypersensitivity to rabeprazole or its components. North America holds a significant market share of over 40% of the global revenue, highlighting the region's strong demand for this medication. The market growth is further supported by well-established healthcare infrastructure and extensive research initiatives. For more detailed information, visit the DailyMed database.

Rabeprazole Sodium

Rabeprazole Sodium, produced by prominent pharmaceutical companies such as those mentioned, including entities like Cipla Ltd and Dr. Reddy's Laboratories Ltd, is a highly effective proton pump inhibitor (PPI) used to treat conditions like gastroesophageal reflux disease (GERD), duodenal ulcers, and Zollinger-Ellison syndrome. The global rabeprazole sodium market is projected to grow at a CAGR of 3.8% from 2022 to 2031, reaching $895.9 million by 2031, with North America holding a significant market share of around 40% in 2024.

Rabeprazole Sodium

Rabeprazole Sodium, particularly from brands like Sun Pharmaceutical, is a leading medication in the treatment of gastroesophageal reflux disease (GERD) and peptic ulcers, with the global market size estimated to reach USD 681.2 million in 2024 and projected to grow at a CAGR of 4.00% from 2024 to 2031. North America, dominated by the United States, holds over 40% of the global revenue, with a market size of USD 272.48 million in 2024. The Asia Pacific region also shows significant growth, with a CAGR of 6.0% during the same period. Rabeprazole Sodium's efficacy is comparable to other proton pump inhibitors like esomeprazole, with studies showing similar symptom relief and safety profiles. The medication's market growth is driven by the increasing prevalence of GERD and peptic ulcers worldwide.

R-prazole

Rabeprazole, marketed by Torrent Pharmaceuticals among others, is a highly effective proton pump inhibitor (PPI) used to treat various acid-related gastrointestinal diseases, including peptic ulcer disease, gastroesophageal reflux disease (GERD), and pathological hypersecretory conditions like Zollinger-Ellison syndrome. Approved for medical use in 1999, rabeprazole has been widely prescribed, with over 1 million prescriptions in the U.S. in 2017, making it the 288th most commonly prescribed medication that year. It is available in 10 and 20 mg delayed-release tablets, ensuring the medication is protected from stomach acid before absorption. Rabeprazole is well-tolerated, even with long-term use, and is indicated for both adults and adolescents aged 12 and above. The drug's efficacy is comparable to other PPIs like omeprazole, making it a reliable choice for managing acid-related disorders. For detailed information about rabeprazole, you can visit the DailyMed website.

Rabonik

Rabonik, a brand by Lupin, is renowned for its high-quality rabeprazole formulations, which have been shown to reduce stomach acid production effectively, alleviating symptoms of acid reflux, heartburn, and diarrhea. In clinical studies, rabeprazole has demonstrated healing rates comparable to omeprazole, with 58% of patients achieving complete healing after 3 weeks and 91% after 6 weeks. This proton pump inhibitor is well-tolerated and provides consistent symptom relief, making it a preferred choice for treating conditions like gastroesophageal reflux disease (GERD) and peptic ulcer disease. The combination of rabeprazole with other medications, such as domperidone, enhances its efficacy by increasing gastrointestinal motility. With numerous brands available, Lupin's Rabonik stands out for its reliability and therapeutic effectiveness.